Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Sprint Bioscience Update - Robust sales and project activity

Sprint Bioscience

Sprint Bioscience has Q2 sales of SEK 16.7m (17.9m in Q1 and SEK 0m in Q2 2023), and the cash balance was SEK 36m (39.9m in Q1 2024). The main difference from last year is the support from recurring services related to VADA (VRK1) (with Day One as a partner) and the VRK1 program. Sprint Bioscience continues to market and attracts interest from potential partners for TREX1 (DISA), NIMA and MASH programs, where the TREX-1 program attracted interest at the “Immuno-Oncology Summit Europe 2024” conference.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Sprint Bioscience Update - Robust sales and project activity

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.